
    
      The study is a randomized controlled trial. Inclusion criteria: Bladder cancer, ability to
      give an informed consent. Exclusion criteria: Previous radiation therapy at the pelvic area,
      ureterocutaneostomy or robot-assisted surgery. The intervention aims to secure that 75% of
      the patient's total energy and protein needs are met during hospitalization.

      Primary outcome: Quality of Life, using the EORTC QLQ-C30 and BLM30 questionnaire. Secondary
      outcomes: Body-weight, Hand Grip strength, biochemical measures, length of hospital stay,
      time to bowel recovery. The follow-up period is 12 weeks. Statistical analysis is performed
      in collaboration with a statistician.
    
  